SCHEMBL13199201

SCHEMBL13199201

O=C(Cc1cccc(O)c1)NNC(=O)c1cccc(Br)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.55
SMN1; SMN2 Q16637 4/20 0.54
HTT P42858 2/20 0.54
NLRP3 Q96P20 1/20 0.54
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C19 P33261 1/20 0.53
ALDH1A1 P00352 4/20 0.50
MAPT P10636 4/20 0.50
RAB9A P51151 2/20 0.50
TDP1 Q9NUW8 2/20 0.48
LMNA P02545 1/20 0.48
ABL1 P00519 1/20 0.48
TSHR P16473 1/20 0.48
RIN1 Q13671 1/20 0.48
POLB P06746 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
KDM4E B2RXH2 1/20 0.47
EGLN2 Q96KS0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13199129 0.90 ALDH1A1 (0.57) NPC1SMN1; SMN2HTTNLRP3MEN1
SCHEMBL13199178 0.87 NPC1 (0.55) NPC1HTTNLRP3MEN1KMT2A
SCHEMBL13199231 0.85 TDP1 (0.62) SMN1; SMN2HTTMEN1KMT2AALDH1A1
SCHEMBL13199210 0.83 NPC1 (0.51) NPC1SMN1; SMN2HTTMEN1KMT2A
SCHEMBL13199164 0.83 KMT2A (0.60) NPC1SMN1; SMN2HTTNLRP3MEN1
SCHEMBL13199145 0.83 SMN1; SMN2 (0.62) NPC1SMN1; SMN2HTTMEN1KMT2A
SCHEMBL13199110 0.82 KDM4E (0.55) HTTMEN1KMT2AALDH1A1TDP1
SCHEMBL14098240 0.81 KDM4E (0.45) NPC1SMN1; SMN2HTTMEN1KMT2A
SCHEMBL13199215 0.81 HPGD (0.65) NPC1SMN1; SMN2HTTNLRP3MEN1
SCHEMBL13199217 0.81 ALDH1A1 (0.53) NPC1HTTNLRP3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767716-B2 Acyl hydrazines as kinase inhibitors, in particular for SGK MERCK PATENT GMBH (DE) 2010-08-03 US disclosed
US-7767716-B2 Acyl hydrazines as kinase inhibitors, in particular for SGK MERCK PATENT GMBH (DE) 2010-08-03 US disclosed
EP-1866280-B1 ACYL HYDRAZIDES AS KINASE INHIBITORS, IN PARTICULAR FOR SGK MERCK PATENT GMBH (DE) 2008-08-13 EP disclosed
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk MERCK PATENT GMBH (DE) 2008-07-10 US disclosed
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk MERCK PATENT GMBH (DE) 2008-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk SGK1, AGK, SGK2 NPC1 2228/4885SMN1; SMN2 4782/4885HTT 2356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.